Jeffrey S. Berns, M.D.
Jeffrey S. Berns, M.D.
Professor of Medicine at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Department: Medicine
Contact information
Renal-Electrolyte & Hypertension Division
Hospital of the University of Pennsylvania
1 Founders Pavilion
Philadelphia, PA 19104
Hospital of the University of Pennsylvania
1 Founders Pavilion
Philadelphia, PA 19104
Office: (215) 615-1677
Fax: (215) 615-1688
Fax: (215) 615-1688
Email:
bernsj@uphs.upenn.edu
bernsj@uphs.upenn.edu
Education:
B.A. (Biology, Psychology)
Indiana University , 1977.
M.D.
Case Western Reserve University, 1981.
Permanent linkB.A. (Biology, Psychology)
Indiana University , 1977.
M.D.
Case Western Reserve University, 1981.
Selected Publications
Berns JS, Kasbekar N: Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists. Clinical Journal of the American Society of Nephrology 1: 117-129, 2006.Berns JS, Kobrin S: Boning up on lanthanum. Seminars in Dialysis 19: 87-89, 2006.
Warburton K, Berns JS: Primary and secondary prevention of cardiovascular disease as patients transition from stage 4-5 CKD to dialysis. Seminars in Dialysis 16: 17-20, 2006.
Sheth N, Sennett B, Berns JS: Rhabdomyolysis and acute renal failure following arthroscopic knee surgery in a college football player taking creatine supplements. Clinical Nephrology 65: 134-137, 2006.
Warburton K, Berns JS (Guest Editors): How should medical therapies be altered with the onset of end-stage renal disease and initiation of dialysis? Seminars in Dialysis 16: 8-24, 2006.
Berns JS: Disorders of Magnesium Homeostasis (Chapter 14) Primer on Kidney Diseases (National Kidney Foundation), 4th edition. A. Greenberg (eds.). Elsevier; Philadelphia, PA, Page: 131-135, 2005.
Berns JS: Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed? Seminars in Dialysis 18: 22-29, 2005.
Berns JS, Mosenkis A: Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis. Hemodialysis International 9: 7-22, 2005.
Berns JS, Fishbane S, Elzein H, Lynn RI, DeOreo PB, Tharpe DL, Meisels IS: The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients. Hemodialysis International 9: 255-263, 2005.
Berns, JS: Summary and Comment: Frequency of sit-down patient care rounds, attainment of clinical performance targets, hospitalization, and mortality in hemodialysis patients. Plantinga LC, Fink NE, Jaar BG, Sadler JH, Coresh J, Klag MJ, Levey AS, Powe NR. J Am Soc Nephrol 2004; 15:3144-3153. Seminars in Dialysis 18: 258-260, 2005.